I'd rather they focus on getting the phase 2b or 3 up and running before starting another indication.
Either way, they're going to need some money.
No mention from company about adding patients, so I'll assume they were not replaced with new patients.
Also, since they discontinued treatment, their data would be excluded.
Only 30 patients going forward. Two discontinued treatment unrelated to study drug (page 7 of November presentation).
They are doing it for the data.
"The second part (PART B) is an open-label extension for an additional period of 52 weeks, so as to establish a longer drug effect for the participants who wish to continue on oral daily dose."
2 patients discontinued treatment. (unrelated to drug)
Page 7 of the November presentation.
Data on pages 11, 12 &14 show n=30
"Losing 50% in a single day is unfathomable"
Welcome to Biotech investing.
PS: I lost 70% in one day on CLVS.
Very unlikely that the FDA will tentative approve a drug for millions based upon results from a safety / dose finding study of 32 patients.
Also, the phase 2A (Part B) extension will not be completed until late September (52 weeks from final enrollment), so commercialization is not happening in six months.
My interpretation of your sentence was that you were claiming that the stock price of a company with stellar performance and soaring profits would be adversely affected by 16 class action lawsuits / investigations.
My point was such a company wouldn't be subject to these actions in the first place.
That said you're correct, it's much ado about nothing.
The company and with it, their stock price will rise or fall based upon the clinical trial results, current and upcoming.
They have stated that the next step is a pivotal phase IIb/III trial so Anavex 2-73 won't be approved based upon results from the current trial.
Unless the stellar performance, soaring profit firm's stock price cratered, there wouldn't be class action lawsuits / investigations. So I still disagree with the first sentence of your statement.
A company with stellar performance and soaring profits isn't going to have 16 lawsuits filed against them for manipulating their stock.